Log In
BCIQ
Print this Print this
 

JB6121

  Manage Alerts
Collapse Summary General Information
Company Janus Biotherapeutics Inc.
DescriptionSmall molecule antagonist of toll-like receptor 7 (TLR7), TLR8 and TLR9
Molecular Target Toll-like receptor 7 (TLR7) ; Toll-like receptor 8 (TLR8)
Mechanism of ActionToll-like receptor 8 (TLR8) antagonist; Toll-like receptor 7 (TLR7) antagonist; Toll-like receptor 9 (TLR9) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/20/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today